The Conversation (0)
March 17, 2025
INN Article Notification
21 May 2024
Cleo Diagnostics
Revolutionising Ovarian Cancer Diagnosis Through Accurate and Early Detection Keep Reading...
27 February 2025
Appendix 4D and Half Yearly Accounts
Cleo Diagnostics (COV:AU) has announced Appendix 4D and Half Yearly AccountsDownload the PDF here. Keep Reading...
31 January 2025
Quarterly activities and cashflow report
Cleo Diagnostics (COV:AU) has announced Quarterly activities and cashflow reportDownload the PDF here. Keep Reading...
09 December 2024
CLEO Further Expands Ovarian Cancer Trial with Siles Health
Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles HealthDownload the PDF here. Keep Reading...
26 November 2024
The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer TrialDownload the PDF here. Keep Reading...
01 May
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today... Keep Reading...
29 April
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's... Keep Reading...
28 April
Fit to Work: GLP-1 and Metabolic Health in the M&A Sector
Biotechnology, pharmaceutical and medtech companies each contributed about 30 percent of deal volume to overall mergers and acquisitions (M&A) activity in 2025.The surge is attributed to rising obesity and diabetes cases, with the 2025 World Obesity Atlas projecting that the total number of... Keep Reading...
23 April
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Contracts signed for Animal Study #2: GLP-1-A26-2Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is... Keep Reading...
22 April
Top 3 Canadian Biotech Stocks in 2026
Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here the Investing News Network profiles the three best-performing Canadian biotech stocks... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Prospectus
2h
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00